DARA Biosciences Company Profile (NASDAQ:DARA)

About DARA Biosciences (NASDAQ:DARA)

DARA Biosciences logoDARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company's primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DARA
  • CUSIP: N/A
  • Web: www.darabiosciences.com/
Average Prices:
  • 50 Day Moving Avg: $0.87
  • 200 Day Moving Avg: $0.87
  • 52 Week Range: $0.67 - $1.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.93
  • P/E Growth: 0.00
  • Net Margins: -228.42%
  • Return on Equity: -145.61%
  • Return on Assets: -100.38%
  • Average Volume: 85,603 shs.

Frequently Asked Questions for DARA Biosciences (NASDAQ:DARA)

What is DARA Biosciences' stock symbol?

DARA Biosciences trades on the NASDAQ under the ticker symbol "DARA."

How were DARA Biosciences' earnings last quarter?

DARA Biosciences Inc (NASDAQ:DARA) released its earnings results on Monday, November, 2nd. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $0.83 million. DARA Biosciences had a negative net margin of 228.42% and a negative return on equity of 145.61%. View DARA Biosciences' Earnings History.

Who are some of DARA Biosciences' key competitors?

Who owns DARA Biosciences stock?

DARA Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include WINGS ESTABLISHMENT (6.20%). View Institutional Ownership Trends for DARA Biosciences.

How do I buy DARA Biosciences stock?

Shares of DARA Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DARA Biosciences' stock price today?

One share of DARA Biosciences stock can currently be purchased for approximately $0.88.

MarketBeat Community Rating for DARA Biosciences (NASDAQ DARA)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  78
MarketBeat's community ratings are surveys of what our community members think about DARA Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for DARA Biosciences (NASDAQ:DARA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for DARA Biosciences (NASDAQ:DARA)
Price Target History for DARA Biosciences (NASDAQ:DARA)
Analysts' Ratings History for DARA Biosciences (NASDAQ:DARA)
No equities research coverage for this company has been tracked by MarketBeat.com


Earnings History for DARA Biosciences (NASDAQ:DARA)
Earnings by Quarter for DARA Biosciences (NASDAQ:DARA)
Earnings History by Quarter for DARA Biosciences (NASDAQ DARA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2015Q3 2015($0.14)($0.14)$0.83 million$1.18 millionViewN/AView Earnings Details
8/12/2015Q215($0.15)($0.14)$0.72 million$0.99 millionViewListenView Earnings Details
5/13/2015Q115($0.12)($0.16)$0.75 million$0.65 millionViewN/AView Earnings Details
3/3/2015Q4 2014($0.11)($0.04)$0.75 million$0.72 millionViewN/AView Earnings Details
11/5/2014Q3 2014($0.13)($0.11)$0.55 million$0.60 millionViewN/AView Earnings Details
8/12/2014Q114($0.18)($0.24)$0.30 million$0.41 millionViewN/AView Earnings Details
5/12/2014Q1 2014($0.35)($0.37)$0.22 million$0.16 millionViewN/AView Earnings Details
11/14/2012Q312($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for DARA Biosciences (NASDAQ:DARA)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.30 EPS


Dividend History for DARA Biosciences (NASDAQ:DARA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for DARA Biosciences (NASDAQ:DARA)
Insider Trades by Quarter for DARA Biosciences (NASDAQ:DARA)
Insider Trades by Quarter for DARA Biosciences (NASDAQ:DARA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/3/2013Christopher G ClementPresidentBuy14,000$0.71$9,940.00View SEC Filing  
5/30/2013Haywood D CochraneDirectorBuy10,000$0.70$7,000.00View SEC Filing  
5/23/2013Timothy James HeadyDirectorBuy10,000$0.75$7,500.00View SEC Filing  
5/17/2013David DrutzCEOBuy25,000$0.70$17,500.00View SEC Filing  
9/17/2012David DrutzCEOBuy25,000$1.06$26,500.00View SEC Filing  
9/11/2012Haywood D CochraneDirectorBuy5,000$0.80$4,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for DARA Biosciences (NASDAQ:DARA)
Latest Headlines for DARA Biosciences (NASDAQ:DARA)
Loading headlines, please wait.



DARA Biosciences (DARA) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.